ArticleMolecular biotechnology2026
Bioencapsulation of Transgenic Nannochloropsis sp. Using Artemia as a Vaccine Delivery System to Zebrafish as a Fish Model Against Vibriosis.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Aquaculture faces decline due to diseases like vibriosis from Vibrio spp. This study aimed to examined the effect of transgenic microalgae Nannochloropsis sp. expressing the antigen OmpK gene originated from Vibrio harveyi and bioencapsulated with Artemia offers any potential as an oral vaccine in zebrafish. Nannochloropsis sp. was transformed using VCP_OMPK_ZA1 vector and successful transformant was incubated with Artemia prior fed to zebrafish. Zebrafish RNA was extracted to investigate immune response activation via gene expression analysis specifically the IgZ, TNF-ɑ, and IL-1β genes. Vaacinated and Unvaccinated fish were then challenged with pathogenic strain to test the efficacy of the oral vaccine. Results showed IgZ and IL-1β expressions increased on Days 7 and 14, while TNF-ɑ upregulated significantly in transgenic-fed zebrafish compared to wild-type. Upon bacterial challenge, transgenic-fed fish exhibited 100% relative percentage survival (RPS) compared to wild-type-fed (RPS = 40%). The histopathological analysis revealed that the fish that were not vaccinated had severe changes such as hemorrhages and necrosis, whereas those that were vaccinated showed only mild changes such as tubular degeneration and muscle regeneration following the bacterial challenge trial. Results indicate transgenic microalgae enhance larval fish immunity against vibriosis, potentially serving as an effective vaccination method.
Indexed as
Identifiers
40965591What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.